Day: July 13, 2020

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) — Pzena Investment Management announced its appointment by St. James’s Place PLC as a manager in its Global Value Fund. Pzena will manage 50% of the fund based on its Global Focused Value strategy, its flagship global strategy managed since 2004.William Lipsey, President of Pzena commented: “Our appointment marks an important milestone in our firm’s history, coming as it does 25 years since the firm’s inception and five years since we opened our London office. Pzena has a proud history of partnering with sophisticated, long-term clients around the world. St. James’s Place is the leading wealth manager in the UK with an impressive history of growth and innovation in the UK retail market who share our commitment to achieving long-term investment success for clients.”Rich...

All dollar amounts are presented in Canadian dollars unless otherwise noted.YERINGTON, Nev., July 13, 2020 (GLOBE NEWSWIRE) — Nevada Copper Corp. (TSX: NCU) (“Nevada Copper” or the “Company’’) is pleased to announce that it has entered into an agreement with Scotiabank, on behalf of a syndicate of underwriters including RBC Capital Markets and National Bank Financial Inc., acting together with Scotiabank as joint Bookrunners, and including Haywood Securities (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to buy on a bought deal basis 643,713,553 units of the Company (the “Units”) at a price of $0.15 per Unit (the “Offering Price”) for aggregate gross proceeds of approximately $97 million (the “Offering”).Each Unit consists of one common share of Nevada Copper (a “Common Share”) and one-half of...

ARLINGTON, Va. and LONDON, July 13, 2020 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, will announce its financial results for the second quarter 2020 on Thursday July 30, 2020.The company will host a conference call to discuss its financial results at 9:30 a.m. Eastern Time on July 30, 2020. A live broadcast of the conference call will be available online at the Investor Relations section of www.willistowerswatson.com.An online replay at www.willistowerswatson.com will be available shortly after the call.  A telephonic replay of the call will also be available for 24 hours at 404-537-3406, conference ID 2568649.ABOUT WILLIS TOWERS WATSONWillis Towers Watson (NASDAQ: WLTW) is a leading global advisory, broking and solutions company that helps clients around the...

Oregon-based Redwood is a “seed-to-smoke” hemp company that offers a lineup of premium, high-quality smokable products made with its own organically-grown hemp. Redwood’s product selection is carried in more than 1,600 U.S. retail stores, which the Company intends to leverage to make Beyond Tobacco™ available to a wider audience of retailers upon its much-anticipated launch planned to occur in Q4 2020. As a result of the proposed acquisition, TAAT plans to benefit from Redwood’s broad production capacity and possibly reduce the cost of producing Beyond Tobacco™ by as much as 50%. Further information regarding this acquisition will be shared in a public conference call to be held at 3:00 pm PDT / 6:00 pm EDT today.LAS VEGAS and VANCOUVER, British Columbia, July 13, 2020 (GLOBE NEWSWIRE) —  TAAT LIFESTYLE & WELLNESS LTD. (CSE:...

ATLANTA, July 13, 2020 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, today announced executive leadership appointments effective July 13, 2020. Jeanine Christian joins DLH as President, Social & Scientific Systems (“S3”), and Jacqueline Everett is appointed as DLH Chief Growth Officer.In her role as President of the Company’s S3 operating unit, Ms. Christian succeeds Kevin Beverly and will lead operations focused on the Public Health and Life Sciences market. Having spent over 20 years in science-based organizations, she most recently led a team of over 300 scientists, clinicians, researchers, and data analysts whose mission it was to translate scientific discovery and technology advances into societal benefits for federal...

Gaithersburg, MD, July 13, 2020 (GLOBE NEWSWIRE) — mPhase Technologies, Inc. (OTCQB: XDSL) (“mPhase” or the “Company”) is providing the following update to highlight significant improvements to its Travel Buddhi platform, which is in final-stage development as an integrated content, planning, booking and engagement solution for global travelers. The Travel Buddhi division is pleased to announce that it is now collaborating with mPhase’s new consumer-oriented technology division, CloseComms, to build an in-destination consumer engagement solution geared toward travelers.This will mark the fourth important component of the Travel Buddhi platform and will be an industry first. This technology integration will give brands tied to the Travel Buddhi platform cross-border portability of their customer engagement programs, via artificial...

Westport, CT, July 13, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the enrollment of adult patients for its Phase II trial for merimepodib, a broad-spectrum, orally administered antiviral drug candidate for the treatment of COVID-19, at four key trial sites. The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures.“Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida. The patients in this trial...

MONTREAL, July 13, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the company’s expansion of its Bioganix CleanCare brand into the Disinfection and Personal Protection Market following successful entry into the hand sanitizing business.EXPANSION INTO DISINFECTION AND PPES MARKETFollowing a successful launch of its hand sanitizing product line, and in view of new demand arising from the ongoing global pandemic, the Company’s wellness brand is expanding its mandate to cover Disinfection and Personal Protection Equipment and Supplies (the “PPES Business”). With the expected introduction of Air Purification and Disinfection System for Home and Office this fall, the Company is also mapping out its entry into disinfection technologies...

SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that it has raised gross proceeds of approximately $90 million through its At-the-Market (ATM) facility with participation based on interest received from RA Capital Management and Invus. The company sold approximately 11.2 million shares at $7.98 per share, the market price at the time of sale. SVB Leerink is acting as lead sales agent and B. Riley FBR is acting as co-sales agent for the ATM facility.The additional funds raised through the ATM facility will support the clinical and preclinical development of Vaxart’s product candidates, to conduct clinical trials, to manufacture its products, and for general...

Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research collaboration with AstraZeneca.The collaboration was initiated in September 2015 to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the delivery of AstraZeneca’s nucleic acid therapeutic compounds. The evaluation of the potential for a further collaboration now runs to the end of 2020.Contact information:                 Per Walday, CEOpw@pcibiotech.noMobile: +47 917 93 429 About PCI Biotech         PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation...